Gemcitabine and cisplatin or oxaliplatin chemotherapy combined with atezolizumab plus bevacizumab for advanced biliary tract cancers: a single-arm trial

Advanced biliary tract cancer (BTC) has a poor prognosis, even after combined chemotherapy of gemcitabine and oxaliplatin (GEMOX). To investigate the efficacy and safety of GEMOX chemotherapy combining atezolizumab and bevacizumab in advanced BTC, the authors designed an open-label, single-arm, phas...

Full description

Saved in:
Bibliographic Details
Published in:Future oncology (London, England) England), 2023-05, Vol.19 (15), p.1029-1035
Main Authors: Wang, Kang, Yu, Hong-Ming, Xiang, Yan-Jun, Cheng, Yu-Qiang, Ni, Qian-Zhi, Guo, Wei-Xing, Shi, Jie, Feng, Shuang, Zhai, Jian, Cheng, Shu-Qun
Format: Article
Language:English
Subjects:
Antineoplastic Combined Chemotherapy Protocols - adverse effects
atezolizumab
bevacizumab
Bevacizumab - adverse effects
Bile Duct Neoplasms - drug therapy
biliary tract cancers
Biliary Tract Neoplasms - drug therapy
Cisplatin - therapeutic use
Gemcitabine
Humans
oxaliplatin
Oxaliplatin - therapeutic use
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Advanced biliary tract cancer (BTC) has a poor prognosis, even after combined chemotherapy of gemcitabine and oxaliplatin (GEMOX). To investigate the efficacy and safety of GEMOX chemotherapy combining atezolizumab and bevacizumab in advanced BTC, the authors designed an open-label, single-arm, phase II clinical trial and will enroll patients with stage IV BTC. The participants will receive GEMOX chemotherapy combined with atezolizumab plus bevacizumab. The primary end point is objective response rate; the secondary end points are overall survival, disease control rate, progression-free survival, time to progression, duration of response and safety. The results of this trial are expected to provide novel, safe and effective treatment options for patients with advanced BTC, which could further improve their prognosis. ChiCTR2100049830 ( ).
ISSN:1479-6694
1744-8301
DOI:10.2217/fon-2022-0189